The price of Can-Fite BioPharma Ltd. (AMEX:CANF) shares last traded on Wall Street fell -6.32% to $4.74.
Based on available information, 2 analysts follow Can-Fite BioPharma Ltd. (AMEX:CANF). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $82.57 and a low of $80.07, we find $81.32. Given the previous closing price of $5.06, this indicates a potential upside of 1507.11 percent. CANF stock price is now -32.81% away from the 50-day moving average and -43.58% away from the 200-day moving average. The market capitalization of the company currently stands at $15.99M.
Among analysts, 1 rate the stock a hold while 1 rate it a buy. Brokers who have rated the stock have averaged $81.32 as their price target over the next twelve months.
With the price target of $7, Maxim Group recently initiated with Buy rating for Can-Fite BioPharma Ltd. (AMEX: CANF)., while ‘Rodman & Renshaw’ rates the stock as ‘Buy’.
There have been several recent changes in the stakes of large investors in CANF stock. A new stake in Can-Fite BioPharma Ltd. shares was purchased by TWO SIGMA SECURITIES, LLC during the first quarter worth $7,000. In total, there are 9 active investors with 1.82% ownership of the company’s stock.
A candlestick chart of Can-Fite BioPharma Ltd. (AMEX: CANF) showed a price of $5.1600 on Tuesday morning. During the past 12 months, Can-Fite BioPharma Ltd. has had a low of $4.57 and a high of $12.90. The fifty day moving average price for CANF is $7.0548 and a two-hundred day moving average price translates $8.4012 for the stock.
The latest earnings results from Can-Fite BioPharma Ltd. (AMEX: CANF) was released for Jun, 2022. For the current quarter, analysts expect CANF to generate $200k in revenue.
Can-Fite BioPharma Ltd.(CANF) Company Profile
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company’s lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.